ArticleCureus2026
Preclinical Histologic and Morphometric Comparison of Poly-L-Lactic Acid Fillers Formulated With Carboxymethyl Cellulose or Non-crosslinked Hyaluronic Acid in a Porcine Model.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly-L-lactic acid (PLLA)-based injectable fillers are used as biostimulatory materials in aesthetic practice. Carrier components may influence particle distribution, hydration behavior, and tissue integration. Comparative preclinical data on PLLA formulations incorporating carboxymethyl cellulose (CMC) versus non-crosslinked hyaluronic acid (HA) remain limited.
objectiveTo compare the longitudinal histologic and morphometric tissue response to PLLA fillers containing CMC or non-crosslinked HA in a porcine model.
methodsIn this paired preclinical study, 10 hybrid female pigs received bilateral subcutaneous injections of PLLA + CMC (Ellure CMC) and PLLA + HA (Ellure HA) at matched abdominal sites. Animals were euthanized at 7, 14, 30, 90, and 180 days post-injection (two animals per time point). Full-thickness skin and subcutaneous adipose tissue (SAT) were harvested from the injection sites. Histologic evaluation was performed using hematoxylin and eosin, Weigert-Van Gieson, and Sirius Red staining. Morphometric assessment included dermal thickness, fibroblast/fibrocyte-associated cellularity, vascular parameters, and collagen type I, collagen type III, and elastin content.
resultsAcross all time points, neither formulation was associated with macroscopic inflammation or histopathologic evidence of overt adverse tissue reaction. Both formulations showed progressive tissue integration characterized by fibroblast/fibrocyte-associated cellular infiltration, neovascular remodeling, and changes in dermal thickness. Mean dermal thickness increased over time in both groups, from 928.6 ± 196.0 µm to 1590.1 ± 125.1 µm for Ellure CMC and from 1231.5 ± 267.8 µm to 1993.4 ± 149.5 µm for Ellure HA between days 7 and 180, with intermediate fluctuation. Collagen and elastin profiles showed broadly similar temporal patterns in skin and SAT in the two groups. Given the limited sample size and the exploratory design, these comparisons should be interpreted descriptively.
conclusionIn this porcine model, PLLA fillers incorporating either CMC or non-crosslinked HA showed comparable descriptive histologic biocompatibility and tissue-remodeling profiles over 180 days. The findings support further controlled studies to determine whether carrier composition influences clinically relevant performance in cosmetic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.